[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA202092158A1 - Комбинированная иммунотерапия бета-глюканом и агонистом cd40 - Google Patents

Комбинированная иммунотерапия бета-глюканом и агонистом cd40

Info

Publication number
EA202092158A1
EA202092158A1 EA202092158A EA202092158A EA202092158A1 EA 202092158 A1 EA202092158 A1 EA 202092158A1 EA 202092158 A EA202092158 A EA 202092158A EA 202092158 A EA202092158 A EA 202092158A EA 202092158 A1 EA202092158 A1 EA 202092158A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glucan
agonist
beta
combined immunotherapy
immunotherapy
Prior art date
Application number
EA202092158A
Other languages
English (en)
Inventor
Нандита Боуз
Грегори Битти
Original Assignee
Хиберселл, Инк.
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хиберселл, Инк., Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания filed Critical Хиберселл, Инк.
Publication of EA202092158A1 publication Critical patent/EA202092158A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к комбинации -глюкана и агониста CD40 для иммунотерапии злокачественных опухолей. Для комбинированной терапии показана синергическая противоопухолевая активность, зависимая от Т-клеток. Неожиданно комбинированная терапия является эффективной против слабо иммуногенных опухолей.
EA202092158A 2018-03-13 2019-03-13 Комбинированная иммунотерапия бета-глюканом и агонистом cd40 EA202092158A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862642210P 2018-03-13 2018-03-13
PCT/US2019/022062 WO2019178236A1 (en) 2018-03-13 2019-03-13 Beta glucan and cd40 agonist combination immunotherapy

Publications (1)

Publication Number Publication Date
EA202092158A1 true EA202092158A1 (ru) 2020-12-25

Family

ID=67908115

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092158A EA202092158A1 (ru) 2018-03-13 2019-03-13 Комбинированная иммунотерапия бета-глюканом и агонистом cd40

Country Status (12)

Country Link
US (1) US20210283168A1 (ru)
EP (1) EP3765018A4 (ru)
JP (1) JP7373152B2 (ru)
KR (1) KR20210038839A (ru)
CN (1) CN112292130A (ru)
AU (1) AU2019234828A1 (ru)
BR (1) BR112020018761A2 (ru)
CA (1) CA3093820A1 (ru)
EA (1) EA202092158A1 (ru)
IL (1) IL277312A (ru)
MX (1) MX2020009510A (ru)
WO (1) WO2019178236A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496508C (en) * 2002-09-04 2014-04-22 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
WO2007084661A2 (en) * 2006-01-17 2007-07-26 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2016007876A1 (en) * 2014-07-10 2016-01-14 Biothera, Inc. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
CN114099671A (zh) * 2014-08-12 2022-03-01 鳄鱼生物科学公司 利用抗cd40抗体的组合疗法
CN107073118B (zh) * 2014-10-29 2022-03-01 西雅图基因公司 非岩藻糖基化抗cd40抗体的剂量和给药
ES2875338T3 (es) * 2014-11-06 2021-11-10 Hibercell Inc Métodos de beta-glucano y composiciones que afectan al microentorno tumoral
JP2018502123A (ja) * 2015-01-20 2018-01-25 イミューンエクサイト， インコーポレイテッド 癌免疫療法のための組成物及び方法
US20170158772A1 (en) * 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof

Also Published As

Publication number Publication date
KR20210038839A (ko) 2021-04-08
JP7373152B2 (ja) 2023-11-02
JP2021518433A (ja) 2021-08-02
US20210283168A1 (en) 2021-09-16
CN112292130A (zh) 2021-01-29
IL277312A (en) 2020-10-29
EP3765018A4 (en) 2022-03-02
MX2020009510A (es) 2021-08-05
AU2019234828A1 (en) 2020-10-22
CA3093820A1 (en) 2019-09-19
BR112020018761A2 (pt) 2020-12-29
EP3765018A1 (en) 2021-01-20
WO2019178236A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
WO2020086726A3 (en) Nerve stimulation for treating migraine and other headache conditions
EP4302835A3 (en) Methods of treating ovarian cancer
MX2022012320A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
EA201591823A1 (ru) Ингибиторы ido
MX2019012464A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
EA201891601A1 (ru) Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей
EA201890968A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2017015896A (es) Agente anticancerigeno.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
EA201891968A1 (ru) Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
JOP20190241B1 (ar) مستحضرات رذاذ إبينيفرين
MX2023004342A (es) Politerapia de antagonistas de union al eje de pd-1 e inhibidores de lrrk2.
PH12021550376A1 (en) Combination therapy
PH12021550448A1 (en) Chronic nightly dosing of lasmiditan for migraine prevention.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
EA202092158A1 (ru) Комбинированная иммунотерапия бета-глюканом и агонистом cd40
MX2021001832A (es) Conjugados para su uso en metodos de tratamiento del cancer.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.